Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.22
-0.09 (-0.68%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
Next >
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
March 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Price Growth & Yield: For That Magical Combo, Leave the U.S.
March 21, 2023
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.
Via
MarketBeat
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
March 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session
March 17, 2023
Via
Investor Brand Network
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
February 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
February 08, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
February 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
February 02, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
January 23, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Named Global Top Employer for Sixth Consecutive Year
January 16, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
January 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
January 09, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
January 05, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
December 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
December 09, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
December 08, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
December 06, 2022
From
Singapore Economic Development Board (EDB)A*STAR
Via
ACN Newswire
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
November 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
November 17, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
November 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
October 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
October 20, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 14, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
Via
FinancialNewsMedia
Topics
Cannabis
Exposures
Cannabis
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
October 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.